Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes

News Conference News ESC 2025

Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes

September 08, 2025

AMALFI: Modest AF Detection With ECG Patch Screening

News Conference News ESC 2025

AMALFI: Modest AF Detection With ECG Patch Screening

Michael O'Riordan

September 05, 2025

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

October 27, 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

September 06, 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

News Conference News ESC 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

September 06, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

News Conference News HRS 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

Michael O'Riordan

May 23, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

News Conference News HRS 2022

Racial/Ethnic Disparities in Anticoagulation Persist in Hospitalized AF Patients

April 29, 2022

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

News Conference News AHA 2021

PALACS: Posterior Left Pericardiotomy Cuts Postop AF After Cardiac Surgery

November 14, 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden

News Conference News ESC 2021

LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden

August 29, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.